S'abonner

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy - 13/01/23

Doi : 10.1016/j.biopha.2022.114061 
Gemma Ferrer-Curriu a, 1, Carolina Soler-Botija a, b, 1, Sandra Charvatova c, d, e, Benjamin Motais c, d, e, Santiago Roura a, b, f, Carolina Galvez-Monton a, b, Marta Monguió-Tortajada a, g, Oriol Iborra-Egea a, Michele Emdin h, i, Josep Lupón g, Alberto Aimo h, i, Juli R. Bagó c, d, e, Antoni Bayés-Genís a, b, g, j, k,
a ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain 
b CIBERCV, Instituto de Salud Carlos III, Madrid, Spain 
c Faculty of Medicine, University of Ostrava, 703 00 Ostrava, Czech Republic 
d Department of Haematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic 
e Faculty of Science, University of Ostrava, 701 00 Ostrava, Czech Republic 
f Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic, Barcelona 08500, Spain 
g Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain 
h Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy 
i Interdisciplinary Center of Health Science, Scuola Superiore Sant'Anna, Pisa, Italy, Fondazione Toscana Gabriele Monasterio, Pisa, Italy 
j Department of Medicine, UAB, Barcelona, Spain 
k Bellvitge Biomedical Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain 

Corresponding authors at: ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, SpainICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti CampusBadalonaSpain

Abstract

Fibrosis is present in an important proportion of myocardial disorders. Injury activates cardiac fibroblasts, which deposit excess extracellular matrix, increasing tissue stiffness, impairing cardiac function, and leading to heart failure. Clinical therapies that directly target excessive fibrosis are limited, and more effective treatments are needed. Immunotherapy based on chimeric antigen receptor (CAR) T cells is a novel technique that redirects T lymphocytes toward specific antigens to eliminate the target cells. It is currently used in haematological cancers but has demonstrated efficacy in mouse models of hypertensive cardiac fibrosis, with activated fibroblasts as the target cells. CAR T cell therapy is associated with significant toxicities, but CAR natural killer cells can overcome efficacy and safety limitations. The use of CAR immunotherapy offers a potential alternative to current therapies for fibrosis reduction and restoration of cardiac function in patients with myocardial fibrosis.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




 : 

Overview of cardiac fibrosis treatments.

Current therapies for cardiac fibrosis are mainly focused on the modulation of fibrogenic cascade. New approaches based on immunotherapy have been develop to combat cardiac fibrosis. CAR T cell therapy has been used to recognize and kill the activated myofibroblasts in preclinical studies although in cancer, CAR T cells present several limitations such as Graft versus Host Disease (GvHD) or cytokine release syndrome (CRS). CAR NK therapy has overcome these limitations in cancer, although it has not yet been tested in myocardial fibrosis. Created with BioRender.com


Overview of cardiac fibrosis treatments.Current therapies for cardiac fibrosis are mainly focused on the modulation of fibrogenic cascade. New approaches based on immunotherapy have been develop to combat cardiac fibrosis. CAR T cell therapy has been used to recognize and kill the activated myofibroblasts in preclinical studies although in cancer, CAR T cells present several limitations such as Graft versus Host Disease (GvHD) or cytokine release syndrome (CRS). CAR NK therapy has overcome these limitations in cancer, although it has not yet been tested in myocardial fibrosis. Created with BioRender.comga1

Le texte complet de cet article est disponible en PDF.

Highlights

New therapeutic approaches are needed to treat cardiac fibrosis.
CAR T cell immunotherapy has antifibrotic effect in cardiac fibrosis mouse models.
CAR NK cells could be an “off-the-shelf” therapy that avoids CAR T cell toxicity.

Le texte complet de cet article est disponible en PDF.

Keywords : Cardiac fibrosis, Immunotherapy, CAR T, Natural killer cells, CAR NK


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 158

Article 114061- février 2023 Retour au numéro
Article précédent Article précédent
  • The role of MEOX1 in non-neoplastic and neoplastic diseases
  • Guoqiang Zeng, Xiaojie Liu, Xiaochen Su, Yuxiong Wang, Bin Liu, Honglan Zhou, Yuantao Wang, Faping Li
| Article suivant Article suivant
  • The role and mechanism of flavonoid herbal natural products in ulcerative colitis
  • Jia-Chen Xue, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Hua-Min Zhang, Li-Li Chen, Cheng-Hao Zhang, Qing-Gao Zhang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.